PATENT
Attorney Docket No. PC9344B (121*254)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ke et al.	
Serial No.: 09/736,051	Group Art Unit: 1617
Filed: December 13, 2000	Examiner: Unassigned
For: COMBINATION THERAPY FOR OSTEOPOROSIS	

Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this 27th day of **March, 2001**.

Jean M. Marshall
(Printed name of person mailing paper)

Jean M. Marshall
(Signature of person mailing paper)

Sir:

AMENDMENT UNDER 37 C.F.R. § 1.607

Prior to examination of the present application, please enter the following amendment.

IN THE CLAIMS:

Please cancel claims 31 and 32 without prejudice or disclaimer.

Please amend claims 34 and 36 as follows:

34. (Amended) A pharmaceutical composition comprising:

a. a therapeutically effective amount of a first compound, said first compound being droloxifene, raloxifene, tamoxifen or idoxifene; and

b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride.

36. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

a. a therapeutically effective amount of a first compound, said first compound being droloxifene, raloxifene, tamoxifen or idoxifene; and

b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride.

Please cancel claims 43 and 44 without prejudice or disclaimer.

Please amend claims 45 and 46 as follows:

45. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

a. a therapeutically effective amount of droloxifene, raloxifene, tamoxifen or idoxifene and a pharmaceutically acceptable carrier in a first unit dosage form;

b. a therapeutically effective amount of a sodium fluoride and a pharmaceutically acceptable carrier in a second unit dosage form; and

c. container means for containing said first and second dosage forms.

46. (Amended) A pharmaceutical composition comprising:

a. a therapeutically effective amount of a first compound, said first compound being

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and

b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride, a parathyroid hormone, or growth hormone.

Please cancel claim 51 without prejudice or disclaimer.

Please amend claim 52 as follows:

52. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

a. a therapeutically effective amount of a first compound, said first compound being

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and

b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride, a parathyroid hormone, or growth hormone.

Please cancel claims 56, 63, and 64 without prejudice or disclaimer.

Please amend claims 65 and 73 as follows:

65. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

a. a therapeutically effective amount of

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline and a pharmaceutically acceptable carrier in a first unit dosage form;

b. a therapeutically effective amount of sodium fluoride, a parathyroid hormone, or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and

c. container means for containing said first and second dosage forms.

73. (Amended) A pharmaceutical composition comprising:

a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and

b. a therapeutically effective amount of a second compound, said second compound being a parathyroid hormone or growth hormone.

Please cancel claim 78 without prejudice or disclaimer.

Please amend claim 79 as follows:

79. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and

b. a therapeutically effective amount of a second compound, said second compound

being a parathyroid hormone or growth hormone.

Please cancel claims 83, 90, and 91 without prejudice or disclaimer.

92. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

a. a therapeutically effective amount of raloxifene, tamoxifen or idoxifene; and a pharmaceutically acceptable carrier in a first unit dosage form;

b. a therapeutically effective amount of a parathyroid hormone or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and

c. container means for containing said first and second dosage forms.

Please add new claims 93-108, as follows:

93. (New) A combination that comprises an estrogen agonist/antagonist and a growth hormone secretagogue.

94. (New) The combination of claim 93, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.

95. (New) The combination of claim 93, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.

96. (New) The combination of claim 93, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolodin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.

97. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 93.

98. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 94.

99. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 95.

100. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 96.

101. (New) The method of claim 97 wherein the condition is osteoporosis.

102. (New) A pharmaceutical composition comprising an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.

103. (New) The composition of claim 102, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.

104. (New) The composition of claim 102, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.

105. (New) The composition of claim 102, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof.

106. (New) A process for making a pharmaceutical composition comprising combining an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.

107. (New) The process of claim 106, wherein the estrogen agonist/antagonist is raloxifene, (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1yl-ethoxy)]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.

108. (New) The process of claim 106, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.